Author Description

Introduction Primary Central Nervous System Lymphoma (pcnsl; Also Called Primary Central Nervous System Diffuse Large B-cell Lymphoma) Is A Rare Non-hodgkin Lymphoma Confined To The Brain, Csf, Csf, Or Eye [1]. The Majority Of Pcnsl Are Diffuse Large B-cell Lymphoma (dlbcl). While It Can Occur At Any Stage Of Adulthood, The Median Age Of Diagnosis Is 65, And The Incidence In The Elderly Population Has Been Rising [2, 3]. Pcnsl Can Occur In The Setting Of Immunosuppression (congenital Immunodeficiency, Human Immunodeficiency Virus Infection, And Acquired Immunodeficiency Syndrome [hiv/aids], Post-transplant Immunosuppression) Or In Immunocompetent Individuals. Pcnsl Is Associated With A Worse Survival Compared To Dlbcl In Other Organs [4]. Most Of The Patients Are Diagnosed By A Stereotactic Biopsy With Only Limited Tissue Availability For Additional Research Into The Underlying Pathophysiology. High-dose Methotrexate-based Regimens Form The Treatment Backbone For Pcnsl Patients. Despite Recent Progress, Results Following Treatment Are Durable In Half Of Patients, And Therapy Can Be Associated With Late Neurotoxicity. Here We Will Review And Summarize The Presentation, Evaluation, And Treatment Of Patients With Pcnsl-- Provided By Publisher.